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OBJECTIVES: We evaluated the impairment of endothelium-dependent and endothelium-independent coronary blood flow reserve 
after administration of intracoronary acetylcholine and adenosine, and its association with hypertensive cardiac disease.
INTRODUCTION: Coronary blood flow reserve reduction has been proposed as a mechanism for the progression of compensated 
left ventricular hypertrophy to ventricular dysfunction.
METHODS: Eighteen hypertensive patients with normal epicardial coronary arteries on angiography were divided into two groups 
according to left ventricular fractional shortening (FS). Group 1 (FS ≥0.25): n=8, FS=0.29 ± 0.03; Group 2 (FS <0.25): n=10, FS= 
0.17 ± 0.03. 
RESULTS: Baseline coronary blood flow was similar in both groups (Group 1: 80.15 ± 26.41 mL/min, Group 2: 100.09 ± 21.51 
mL/min, p=NS). In response to adenosine, coronary blood flow increased to 265.1 ± 100.2 mL/min in Group 1 and to 300.8 ± 113.6 
mL/min (p <0.05) in Group 2. Endothelium-independent coronary blood flow reserve was similar in both groups (Group 1: 3.31 
± 0.68 and Group 2: 2.97 ± 0.80, p=NS). In response to acetylcholine, coronary blood flow increased to 156.08 ± 36.79 mL/min 
in Group 1 and to 177.8 ± 83.6 mL/min in Group 2 (p <0.05). Endothelium-dependent coronary blood flow reserve was similar in 
the two groups (Group 1: 2.08 ± 0.74 and group Group 2: 1.76 ± 0.61, p=NS). Peak acetylcholine/peak adenosine coronary blood 
flow response (Group 1: 0.65 ± 0.27 and Group 2: 0.60 ± 0.17) and minimal coronary vascular resistance (Group 1: 0.48 ± 0.21 
mmHg/mL/min and Group 2: 0.34 ± 0.12 mmHg/mL/min) were similar in both groups (p= NS). Casual diastolic blood pressure 
and end-systolic left ventricular stress were independently associated with FS. 
CONCLUSIONS: In our hypertensive patients, endothelium-dependent and endothelium-independent coronary blood flow 
reserve vasodilator administrations had similar effects in patients with either normal or decreased left ventricular systolic 
function.
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INTRODUCTION
Left ventricular hypertrophy (LVH) in the context of 
systemic hypertension is an independent risk factor for 
sudden death, ventricular arrhythmia, myocardial ischemia, 
and heart failure.1 Many pathophysiological mechanisms, 
including reductions in coronary blood flow reserve 
(CBFR), have been proposed to explain the progression of 
compensated LVH to ventricular dysfunction.2 Coronary 
microcirculation alterations in hypertension have already 
been reported in a previous study.3 Antony et al. (1993) 
showed that CBFR was low in hypertensive patients both 
with and without LVH, but that following one year of 
antihypertensive treatment, reserve became normal in the 
non-LVH patients, suggesting that hypertension treatment 
may normalize compromised coronary blood flow.4 
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In patients with normal endothelium-independent 
CBFR, LV maladaptation as a result of inadequate flow 
may be explained by the occurrence of coronary vasculature 
endothelial dysfunction.3 This phenomenon has been 
described in the peripheral and coronary circulation of 
dilated cardiomyopathy patients.5 Endothelial dysfunction 
in hypertension has been shown in peripheral and coronary 
vasculature in patients without LV systolic dysfunction.3,6 
It is possible that impairment of endothelium-dependent 
coronary vasodilatation capacity is one of the mechanisms 
responsible for inadequate myocardial flow, and therefore 
contributes to ventricular maladaptation before the 
development of morphological alterations that affect the 
capacity of endothelium-independent vasodilatation. 
Given the multitude of factors involved in LV 
decompensation, no study to date has determined the 
roles of endothelium-dependent and independent coronary 
reserve compromise in different grades of hypertensive heart 
disease.
The goals of this study were: (1) to evaluate endothelium-
dependent and independent coronary artery vasodilatation 
compromise in hypertensive patients with reduced or preserved 
fractional shortening; (2) to evaluate whether an association 
exists between LV dysfunction progression and endothelium-
dependent and independent coronary reserve decrease; (3) to 
evaluate the influence of clinical, structural, and functional 
factors to LV maladaptation in hypertensive patients.
METHODS
Study population and groups 
At our institution, 33 hypertensive patients underwent 
clinical evaluation and additional routine laboratory 
examinations, 12-lead electrocardiography, chest X-ray, 
and transthoracic echocardiography. All patients were in 
NYHA functional class I or II, and the initial evaluation was 
performed using conventional antihypertensive medication. 
Inclusion criteria were based on hypertension history, 
blood pressure (BP) levels above 140X90 mm Hg recorded 
on at least three occasions with the patient in a sitting position 
after resting for at least 5 minutes.7 Exclusion criteria were 
serum creatinine >2.0 mg/dL; presence of coronary artery 
stenosis >30%; contraindication for adenosine (previous 
chronic obstructive pulmonary disease, use of xanthine, 
bradyarrhythmia) or femoral access catheterization; iodate 
contrast allergy; use of acetylsalicylic acid, which could 
interfere with the behavior of coronary blood flow;8 and the 
presence of any other systemic or heart disease.
From the initial selected population, 12 patients were 
excluded due to significant coronary artery disease and three 
others were excluded due our inability to obtain an adequate 
coronary flow curve. Therefore, 18 patients were studied, 
divided into 2 groups based on left ventricular fractional 
shortening (LVFS). Group 1 exhibited preserved ventricular 
function and LVFS ≥25%, and Group 2 exhibited ventricular 
dysfunction and LVFS <25%. Group 1 comprised 8 patients 
(3 male, 50.88 ± 14.65 years). Group 2 comprised 10 patients 
(7 male, 48.7 ± 12.45 years). Baseline characteristics of the 
two groups are shown in Table 1. Patients from Group 1 were 
treated with hydrochlorothiazide (50 mg/day), methyldopa 
(750-1500 mg/day), amlodipine (10 mg/day), angiotensin 
conversion enzyme inhibitors (captopril 100-150 mg/day 
or enalapril 40 mg/day) or angiotensin receptor blocker 
(losartan 25-100 mg/day). Group 2 patients were treated 
with hydrochlorothiazide (50 mg/day), methyldopa (750-
1500 mg/day), clonidine (0.2 mg/day), nifedipine (60 mg/
day), angiotensin conversion enzyme inhibitors (captopril 
Table 1 - Baseline characteristics of the two groups of patients
Group 1 Group 2 P value
Number of patients n=8 N=10
Age (years) 50.88±14.65 48.7±12.45 0.7377
Male 3/8 (37.5%) 7/10(70%) 0.3416
Race 4 Caucasians (50%) 3 Caucasians (30%)
4 Afro-americans (50%) 6 Afro-americans (70%) 0.3441
Body surface area (m2) 1.68±0.13 1.60±0.20 0.3640
Total cholesterol (mg/dL) 191.63±27.00 184.80±19.94 0.5455
LDL-cholesterol (mg/dL) 123.63±17.74 114.00±25.18 0.3750
HDL-cholesterol (mg/dL) 48.75±12.87 46.20±15.65 0.7157
Triglycerides (mg/dL) 97.00±20.81 123.00±110.98 0.7223
Glucose (mg/dL) 99.00±6.76 96.10±12.07 0.5533
Urea (mg/dL) 31.25±7.59 40.60±8.72 0.0295
Creatinine (mg/dL) 0.94±0.14 1.13±0.23 0.0558
Hemoglobin (g/dL) 13.68±0.78 13.53±0.79 0.7023
Hematocrit (%) 40.25±1.49 40.60±2.55 0.4383
Sodium (mEq/L) 140.38±1.41 138.80±2.25 0.1043
Potassium (mEq/L) 4.04±0.49 4.25±0.31 0.2778
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150 mg/day or enalapril 10-40 mg/day), digoxin (0.25 mg/
day), furosemide (40-80 mg/day), and spironolactone (25-
100 mg/day). 
All patients had been diagnosed with hypertension at 
least 4 years prior to our study, and had been receiving initial 
antihypertensive treatment for at least 3.5 years. 
Our hospital’s ethics committee approved this study 
protocol, # 696/00, and patients signed an informed consent 
form, in compliance with ethics committee guidelines.
Echocardiography study 
To determine LV structure and funct ion,  an 
echocardiographic study was performed, and the following 
parameters were determined according to American Society 
of Echocardiography recommendations:9 LV end-diastolic 
diameter (LVDD), LV end-systolic diameter (LVSD), 
interventricular septum (IVS), and posterior wall (PW) 
systolic and diastolic thickness. The equipment used was 
an ACUSON Sequoia 512 model (Acuson Corporation, 
Mountain View, California, EUA) equipped with a 
multifrequency transducer, model 3V2c. 
We calculated LV mass corrected by body surface area 
(BSA) to obtain LV mass index (LVM).10 LVEF relative wall 
thickness (RWT).9 and LV end-systolic stress (LVFSS) were 
also studied.11 
Hemodynamic study 
Patients underwent right cardiac catheterization 
performed by the thermodilution method using a Swan-Ganz 
catheter, model 139f75 (Baxter Healthcare Corporation, 
Irvine, CA, USA) for pressure and cardiac output 
measurements.12 To measure LV aorta pressure, left cardiac 
catheterization was performed with cinecoronariography 
using non-ionic iopamidol iodated contrast (Iopamiron 
370, Schering do Brasil, Química e Farmacêutica Ltda), 
and an intracoronary Doppler blood flow study. No left 
ventriculography was performed, in order to decrease 
the contrast dosage. Patients with significant coronary 
obstruction (>30%) did not undergo the coronary blood 
flow study. 
Antihypertensive medication and vasodilative drugs were 
withheld for 24 to 48 hours before the study. Patients were 
advised to avoid eating and taking medications containing 
xanthines, due to the inhibiting effect these substances have 
on adenosine.
Coronary arterial flow study 
Following the hemodynamic and cinecoronariography 
study, a dose of 10,000 UI heparin was administered by IV 
bolus. Afterward, a 6F or 7F (Boston Scientific Scimed, Inc., 
Maple Grove, MN, USA) catheter guide was positioned 
in the left coronary artery ostium. A 0.014-inch FloWire 
model guide wire (Cardiometrics, Inc., Mountain View, CA) 
with a FloMap model Doppler transducer (Cardiometrics, 
Inc., Mountain View, CA) on its extremity was introduced 
through the catheter and positioned in the proximal third of 
the anterior descending artery. 
The following variables were evaluated: epicardial 
luminal cross-sectional area (CSA) at the location where 
flow velocity was measured, and coronary blood flow 
(CBF)13 Endothelium-independent hyperemia induction was 
performed with adenosine (Adenocard, Libbs Farmacêutica 
Ltda, Brasil), 18µg (AD1) and 36µg (AD2), by IV bolus3 
Next, angiography was performed to determine cross-
sectional diameter under these conditions to calculate CBF 
with AD1 and AD2. The greatest flow obtained (CBFRm ad) 
was used to calculate coronary blood flow reserve (CBFR), 
according to the formula:
CBFRe i=CBFRm ad/CBFRb 
where: CBFRe-i = coronary blood flow reserve endothelium-
independent; CBFRm ad = maximum coronary blood flow 
reserve with adenosine; CBFRb = coronary blood flow 
reserve baseline.
Acetylcholine was administered at a velocity of 5 mL/
min for 2 minutes, with target concentrations of 10-7 (AC1), 
10-6 (AC2), and 10-5 M (AC3) [14]. The endothelium-
dependent CBFR was calculated according to the formula:
CFRed=CBFRm ac/CBFRb 
where: CBFRe i = endothelium-dependent coronary blood 
flow reserve; CBFRm ac= maximum coronary arterial flow 
reserve with acetylcholine; CBFRb= coronary blood flow 
reserve baseline.
In order to evaluate whether infusion through 
acetylcholine dilution could increase flow due to shear stress, 
the acetylcholine study was preceded by a saline infusion at 
5mL/min velocity for 2 minutes.6 To evaluate the extent of 
endothelium-dependent coronary vasodilation, the highest 
CBF obtained with acetylcholine (CBFRm ac) was divided 
by the highest CBF obtained with adenosine (CBFRm ad).3
Minimal coronary vascular resistance (RESISTmin) 
was calculated by evaluating the ratio between mean blood 
pressure (MBP ad) and maximum coronary blood flow using 
adenosine.3,8
At the end of the procedure, a 300 µg nitroglycerin dose 
(Tridil, Cristália Produtos Químicos Farmacêuticos Ltda, 
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Brazil) was administered by IV bolus with the patient at 
baseline to evaluate endothelium-independent vasodilation 
capacity of the anterior descending coronary artery. Two 
minutes later, angiography was performed to determine the 
cross-sectional diameter under these conditions and the time 
necessary to achieve maximum epicardial artery dilation.3
Statistical analysis
Groups 1 and 2 were compared using a Student t test 
or a Wilcoxon’s test for independent samples in relation 
to continuous variables evaluated at one time, in relation 
to RESISTmin and in relation to the adenosine and 
acetylcholine maximum flow ratio. For categorized variables, 
Groups 1 and 2 were compared using Fisher’s exact test.
Group comparisons relating to CBF, CFV, CF, SBP, DBP 
and MBP variables throughout baseline and adenosine 1 and 
2 dose evaluations were performed using profile analysis. 
The same analyses were performed for group comparisons 
throughout baseline and acetylcholine 1, 2, and 3 dose 
evaluations, baseline and saline evaluations, and baseline and 
nitroglycerin evaluations. Occasionally, differences observed 
in hemodynamic variable behaviors (BP and heart rate) in 
response to vasodilating drugs (adenosine and acetylcholine) 
were considered in the endothelium-dependent and 
independent CFR calculation, using a covariance analysis. 
The association of LVFS variables with SBP, DBP, MBP, 
age, LVM, RWT, LVFSS, RESISTmin, CBFRe i and CBFRe 
d variables (the latter 2 adjusted by covariance analysis) were 
evaluated using Pearson’s correlation coefficient and multiple 
linear regression. A stepwise method was adopted to identify 
variables with an entry significance level equal to 0.10 and an 
exit equal to 0.05. Data are expressed as means and standard 
deviations. p < 0.05 was considered significant.
RESULTS
Demographic and laboratory variables
No differences were found between groups in terms of 
age, sex, race, BSA, tabagism, or family history of coronary 
insufficiency. No difference was identified between groups 
based on laboratory test results, including total cholesterol 
level, LDL-cholesterol, HDL-cholesterol, or triglycerides, all 
of which were within normal ranges. Urea was statistically 
higher and creatinine tended to be higher in Group 2, but all 
values were still within the normal ranges (Table 1). 
Left ventricle structure and function 
The LVDD (54.2 ± 5.9 mm x 69.0 ± 10.7 mm), LVSD 
(38.3 ± 4.4 mm x 57.4 ± 9.6 mm), LVM (201.5 ± 65.7 
g/m2 x 310.4 ± 99.1 g/m2), and LVFSS (81.0 ± 19.9 103 dyn/
cm2 x 123.99 ± 28.13 103 dyn/cm2) were lower in Group 1, 
and the RWT (0.44 ± 0.1 x 0.34 ± 0.1) was higher in Group 
1 (p <0.05). No differences between IVS and PW thickness 
measurements were identified. 
Hemodynamic study 
Aorta root blood pressures were higher in Group 1 
compared to Group 2 [systolic (168.1 ± 28.5 mm Hg x 
136.6 ± 31.0 mm Hg), diastolic (90.6 ± 11.5 mm Hg x 75.0 
± 12.3 mm Hg) and mean (117.4 ± 13.7 mm Hg x 95.9 ± 
15.6 mm Hg)] (p <0.05). Cardiac index also tended to be 
higher in Group 1 (3.3 ± 0.6 L/min.m2 x 2.7 ± 0.5 L/min.m2) 
(p=0.0524). LV pulmonary capillary, central venous, and 
final diastolic pressures, pulmonary blood pressure (systolic, 
diastolic, and median), and systemic and pulmonary vascular 
resistance rates were not statistically different between 
groups.
Coronary blood flow 
Intracoronary drug administration was well tolerated. 
Saline solution infusion did not significantly change the 
anterior descending coronary artery diameter (Group 1, 
from 2.98 ± 0.58 to 3.00 ± 0.50 mm; Group 2, from 3.49 
± 0.34 to 3.54 ± 0.30 mm; p=0.2913), the coronary blood 
flow velocity (Group 1, from 23.88 ± 8.01 to 25.00 ± 8.77 
cm/sec; Group 2, from 21.10 ± 4.98 to 22.30 ± 6.62 cm/
sec; p=0.0850), heart rate (Group 1, from 73.88 ± 8.97 to 
72.88 ± 10.22 bpm; Group 2, from 68.40 ± 9.77 to 67.70 ± 
10.24 bpm; p=0.1712), SBP (Group 1, from 164.88 ± 25.39 
to 161.50 ± 26.04 mmHg; Group 2, from 130.80 ± 26.81 to 
131.40 ± 27.22 mmHg; p=0.2464) and MBP (Group 1, from 
121.75 ± 14.87 to 118.13 ± 13.94 mmHg; Group 2, from 
97.10 ± 14.41 to 97.70 ± 15.38 mmHg; p=0.1551). DBP 
decreased (Group 1, from 91.38 ± 10.98 to 88.88 ± 10.20mm 
Hg; Group 2, from 77.40 ± 11.47 to 75.10 ± 12.02 mm Hg; 
p=0.0176), comparably in both groups (p=0.9136).
Adenosine coronary blood flow 
Adenosine results are listed in Table 2. Profile analysis 
showed no differences in heart rate between the groups 
(p=0.2933) and no change in the two adenosine dose 
administrations (p=0.3139), in either group (p=0.2225). SBP 
and MBP were lower in Group 2 (p=0.0207 and p=0.0159, 
respectively), while DBP showed no difference between 
groups (p=0.0589). No SBP changes occurred in the two 
adenosine dose administrations at baseline (p=0.7207) 
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in either group. DBP and MBP decreased (p=0.0005) 
comparably in both groups (p=0.6107 and p=0.1637 for DBP 
and MBP, respectively) for both adenosine doses in relation 
to baseline values. No difference in DBP (p=0.8332) or 
MBP (p=0.2008) were found from the two adenosine dose 
administrations in either group.
Coronary blood flow velocity did not differ between 
groups (p=0.1715) and increased (p<0.0001) comparably 
in both groups (p=0.2716) in relation to baseline values 
(p<0.0001 for the two adenosine dose administrations). No 
difference was found in coronary blood flow velocity from 
the first to the second adenosine dose administrations in 
either group (p=0.6573, Figure 1). 
Anterior descending coronary artery diameter was 
greater in Group 2 than in Group 1 (p=0.0313). An increase 
(p=0.0005) in the anterior descending artery diameter was 
observed at the two adenosine dose administrations, which 
was comparable between groups (p=0.6605) compared 
with baseline values. No difference in the two adenosine 
dose administrations diameters occurred in either group 
(p=0.0734). Profile analysis showed that coronary blood 
flow did not differ between groups and increased comparably 
in relation to baseline values in both. No coronary blood 
flow difference from the first to the second adenosine dose 
administrations was evidenced in either group (Figure 1).
Acetylcholine coronary blood flow 
Acetylcholine results are listed in Table 3. Profile 
analysis showed that heart rate did not differ between 
groups (p>0.05) and changed differently in the two groups 
(p=0.0498). Heart rate at AC3 in relation to baseline values 
increased in Group 2 (p=0.0393), but decreased in Group 1 
(p=0.0270). No difference in heart rate from AC1 to AC2 
(p=0.08680) and from AC2 to AC3 (p=0.3101) occurred in 
Group 2, while in Group 1, heart rate decreased from AC1 
to AC2 (p=0.0257), and no difference occurred from AC2 to 
AC3 (p=0.8835).
SBP, DBP, and MBP were lower in Group 2 (p=0.0425, 
p=0.0368, and p=0.0157, respectively). No differences in 
SBP, DBP, and MBP (p=0.8104, p=0.2526, and p=0.2455, 
respectively) occurred with the three acetylcholine dose 
administrations in relation to baseline values in either 
group.
Coronary blood flow velocity did not differ between 
groups (p=0.4706) and increased (p=0.0061) comparably 
(p=0.8837) in relation to baseline values in both (AC1, 
p=0.0167; AC2, p=0.0008; AC3, p=0.0011). An increase 
(p=0.0028) from AC1 to AC2 also occurred in both groups, 
and no coronary blood flow velocity difference was identified 
from AC2 to AC3 in any group (p=0.2583).
The anterior descending coronary diameter did not differ 
between the groups (p=0.1238) and increased (p=0.0289) 
comparably in both groups (p=0.6164) in relation to 
Table 2 - Hemodynamic variables, coronary blood flow 
velocity, and anterior descending coronary artery diameter 
with the use of adenosine
Variables Group 1 Group 2
HR-Basal (bpm 73.88 ± 8.97 68.40 ± 9.77
HR-AD1 (bpm) 74.00 ± 8.54 69.20 ± 7.73
HR-AD2 (bpm) 73.75 ± 8.10 71.20 ± 8.32
SBP-Basal (mm Hg) 164.88 ± 25.39 130.80 ± 26.81*
SBP-AD1 (mm Hg) 162.25 ± 29.74 130.10 ± 29.47*
SBP-AD2 (mm Hg) 163.63 ± 26.73 129.40 ± 29.74*
DBP-Basal (mm Hg) 91.38 ± 10.98 77.40 ± 11.47
DBP-AD1 (mm Hg) 80.13 ± 11.29# 68.20 ± 14.85#
DBP-AD2 (mm Hg) 79.25 ± 11.88# 70.10 ± 17.15#
MBP-Basal (mm Hg) 121.75 ± 14.87 97.10 ± 14.41*
MBP-AD1 (mm Hg) 111.50 ± 17.08# 93.40 ± 18.77*#
MBP-AD2 (mm Hg) 107.25 ± 14.62# 90.40 ± 18.51*#
CFV-Basal (cm/seg) 23.88 ± 8.01 21.10 ± 4.98
CFV-AD1 (cm/seg) 62.88 ± 17.52# 51.80 ± 17.89#
CFV-AD2 (cm/seg) 65.25 ± 20.45# 51.00 ± 17.42#
D-Basal (mm) 2.98 ± 0.58 3.49 ± 0.34*
D-AD1 (mm) 3.10 ± 0.60# 3.67 ± 0.37*#
D-AD2 (mm) 3.21 ± 0.64# 3.74 ± 0.42*#
AD1=18 µg adenosine; AD2=36 µg adenosine; HR=heart rate; SBP=systolic 
blood pressure; DBP=diastolic blood pressure; MBP=mean blood pres-
sure; CFV=coronary flow velocity; D=anterior descending artery diameter; 
*=p<0.05 vs. group 1; #=p<0.05 vs. basal
Figure 1 - Effect of intracoronary administration of adenosine (AD1=18 
µg. AD2=36 µg) on coronary blood flow in Groups 1 and 2. Profile analysis 
showed that coronary blood flow did not differ between groups and increased 
comparably in relation to baseline values in both. No coronary blood flow 
difference from the first to the second adenosine dose administrations was 
evidenced in either group.
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baseline values (AC1, p=0.0261; AC2, p=0.0434). AC3 
diameter was comparable with baseline in both groups 
(p=0.1211). No diameter changes were noted from AC1 to 
AC2 (p=0.4530). A diameter decrease occurred from AC2 
to AC3 (p=0.0073).
Two patients from Group 1 and four from Group 2 
exhibited coronary artery spasms with the highest dose 
of acetylcholine (AC3). No analysis of these spasms was 
performed because they occurred in arterial segments that 
were not included in our measurements for the coronary blood 
flow calculation. No statistical differences between groups 
were identified in relation to the occurrence of these spasms.
Profile analysis showed that coronary blood flow did 
not differ between the groups but increased comparably in 
both in relation to baseline values. Coronary blood flow also 
increased between AC1 and AC2, but not from AC2 to AC3 
in any group (Figure 2).
The maximum coronary blood flow ratios using 
acetylcholine (CBFRm ac) and adenosine (CBFRm ad) were 
statistically comparable (p=0.6361) between Group 1 (0.65 
± 0.27) and Group 2 (0.60 ± 0.17).
Endothelium-independent coronary blood flow reserve 
As SBP and DBP differed between the groups, 
endothelium-independent CBFR individual values were 
adjusted to baseline SBP and DBP values in the covariance 
analysis (COVAN). No endothelium-independent CBFR 
difference was seen between groups (p=0.4652).
Endothelium-dependent coronary blood flow reserve 
Individual endothelium-dependent CBFR values were 
adjusted to baseline SBP and DBP values and were replaced 
by the difference between maximum and baseline CF in the 
covariance analysis (COVAN), as SBP and DBP differed 
between the groups and CBF was differently affected in 
each group. No endothelium-dependent CBFR difference 
occurred between groups (p=0.0772).
Minimal coronary blood resistance 
RESISTmin did not differ between groups. The mean 
value for Group 1 was 0.48 ± 0.21 mm Hg/mL/min, and for 
Group 2 it was 0.34 ± 0.12 mm Hg/mL/min (p=0.0874).
Table 3 - Hemodynamic variables, coronary blood flow 
velocity, and anterior descending coronary artery diameter 
with the use of acetylcholine
Variables GROUP 1 GROUP 2
HR-Basal (bpm 73.88 ± 8.97 68.40 ± 9.77
HR-AC1 (bpm) 73.88 ± 8.11 68.70 ± 8.56
HR-AC2 (bpm) 71.13 ± 10.02a 68.80 ± 8.50
HR-AC3 (bpm) 69.14 ± 8.25# 69.22 ± 9.67#
SBP-Basal (mmHg) 164.88 ± 25.39 130.80 ± 26.81*
SBP-AC1 (mmHg) 166.75 ± 23.33 131.70 ± 31.13*
SBP-AC2 (mmHg) 164.25 ± 26.52 126.90 ± 39.76*
SBP-AC3 (mmHg) 166.00 ± 27.28 138.11 ± 28.09*
DBP-Basal (mmHg) 91.38 ± 10.98 77.40 ± 11.47*
DBP-AC1 (mmHg) 92.75 ± 12.00 77.20 ± 12.63*
DBP-AC2 (mmHg) 89.38 ± 11.73 73.70 ± 22.31*
DBP-AC3 (mmHg) 88.71 ± 9.23 80.22 ± 12.53*
MBP-Basal (mmHg) 121.75 ± 14.87 97.10 ± 14.41*
MBP-AC1 (mmHg) 124.50 ± 14.54 99.50 ± 17.33*
MBP-AC2 (mmHg) 120.13 ± 14.72 95.40 ± 27.50*
MBP-AC3 (mmHg) 119.00 ± 15.09 104.11 ± 14.90*
CFV-Basal (cm/seg) 23.88 ± 8.01 21.10 ± 4.98
CFV-AC1 (cm/seg) 29.63 ± 13.61# 24.80 ± 10.60#
CFV-AC2 (cm/seg) 41.00 ± 19.87# a 30.10 ± 14.97# a
CFV-AC3 (cm/seg) 43.14 ± 25.40# 34.67 ± 17.45#
D-Basal (mm) 2.98 ± 0.58 3.49 ± 0.34
D-AC1 (mm) 3.06 ± 0.72# 3.62 ± 0.40#
D-AC2 (mm) 3.03 ± 0.67# 3.60 ± 0.34#
D-AC3 (mm) 3.06 ± 0.71t 3.26 ± 0.55t
AC1=10-7 M acetylcholine; AC2=10-6 M acetylcholine; AC3=10-5 M ace-
tylcholine; HR= heart rate; SBP= systolic blood pressure; DBP= diastolic 
blood pressure; MBP= mean blood pressure; CFV= coronary flow velocity; 
D= anterior descending artery diameter; *=p<0.05 vs. group 1; # =p<0.05 
vs. basal; a =p<0.05 vs. AC1; t =p<0.05 vs. AC2
Figure 2 - Effect of intracoronary administration of acetylcholine (AC1=10-7 
M. AC2=10-6 M. AC3=10-5 M) on coronary blood flow in Groups 1 and 2. 
Profile analysis showed that coronary blood flow did not differ between 
the groups but increased comparably in both in relation to baseline values. 
Coronary blood flow also increased between AC1 and AC2, but not from 
AC2 to AC3 in any group.
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Nitroglycerin epicardial anterior coronary artery vaso-
dilatation 
The anterior descending coronary artery diameter was 
larger (p=0.0253) in Group 2 (baseline=3.49 ± 0.34 mm; 
NG=3.91 ± 0.36 mm) than in Group 1 (baseline=2.9 8 ± 
0.58 mm; NG=3.35 ± 0.60 mm) and increased (p=0.0002) 
comparably (p=0.8076) in both groups in relation to baseline 
values. Profile analysis showed that heart rate increased 
(p=0.0244), while SBP (p=0.0122), MBP (p=0.0035), and 
DBP (p=0.0118) decreased with nitroglycerin administration 
comparably in both groups.
LV fractional shortening and predictive factors
Pearson’s correlation coefficient values with respective 
statistical probabilities of the simple linear regression 
analysis between LVFS and clinical study variables are 
shown in Table 4. Casual blood pressure measurements (SBP, 
DBP, MBP) were used in this analysis. A stepwise multiple 
linear regression analysis identified DBP and LVFSS as 
variables that were independently correlated to LVFS 
(adjusted r2 =0.7109; DBP p=0.0045; LVFSS: p=0.0002).
DISCUSSION
Our study included hypertensive patients without other 
risk factors for heart disease (with the exception of one 
smoker). This study design allowed us to evaluate to the 
extent possible the independent effect of hypertension on 
CBFR. Although the study population consisted of patients 
with hypertensive heart disease who had been prescribed 
significant quantities of hypertensive medication, all were 
within NYHA functional classes I or II. In order to reduce 
the influence of hypertensive drugs on our results, all such 
medications were withheld for 24 to 48 hours before the 
study, as is common practice in the literature.3,5,6,8 It is 
widely accepted that one should wait 5 half-lives to eliminate 
the effects of a given drug - for some of the drugs used, 5 
half-lives was longer than our chosen suspension duration. 
However, because our patients were at risk of hemodynamic 
decompensation, we did not consider it ethically acceptable 
to withhold their medications for an extended period.
Groups were assigned based on LV systolic function with 
statistically equivalent demographic and laboratory variables, 
and can therefore be considered comparable. However, 
echocardiographic evaluation confirmed a higher grade of 
LV remodeling and LV dysfunction in Group 2 compared 
to Group 1.
Hemodynamic characteristics 
Hemodynamic variables confirmed the good clinical 
compensation status of the patients, as filling pressures and 
cardiac index were at acceptable levels. We also note that no 
patients exhibited pulmonary artery hypertension. Groups 
did not differ in respect of ventricular filling pressures, 
a variable that could interfere with coronary blood flow 
measurements. The difference in LV afterload was evident 
because higher pressure levels were obtained at the aortic 
root in Group 1. The ultimate impact of CBFR in the 
context of this perfusion difference was not observed during 
the RESISTmin calculation, because no differences were 
identified between groups.
Coronary blood flow reserve 
We chose to use nitroglycerin at the end of the study to 
evaluate whether the epicardial coronary artery response 
to an endothelium-independent stimulus was preserved. 
Therefore, in the event this arterial segment did not 
respond to flow induced by microcirculation dilation, we 
could conclude that it did not occur due to an inability of 
the vessel’s medium layer to respond to a vasodilatation 
stimulus, but rather due to a deficiency in the endothelium 
response to the increase in shear stress. Furthermore, as we 
observed, intracoronary nitroglycerin induces significant 
systemic hemodynamic alterations, such as a decrease in 
BP and an increase in heart rate, a fact that may interfere 
with CBF measurements. We performed isolated saline 
infusion, with a documented absence of measurable effects 
that supported the reliability of our results.
Table 4 - Pearson’s linear correlation between LVFS and 
study variables
Variables r p
SBP 0.51 0.0299
DBP 0.58 0.0114
MBP 0.57 0.0137
Age 0.01 0.9797
LVM -0.40 0.1037
RWT 0.68 0.0018
LVFSS -0.75 0.0004
RESISTmin 0.26 0.3007
CBFRe i 0.60 0.0137
CBFRe d 0.37 0.1257
SBP=systolic blood pressure; DBP=diastolic blood pressure; MBP=mean 
blood pressure; LVM= indexed left ventricular mass; RWT=relative wall 
thickness; LVFSS=LV end-systolic stress; CBFRe i=coronary blood 
flow reserve, endothelium independent; CBFRe d=coronary blood flow 
reserve, endothelium dependent.
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Our data suggest that endothelium-dependent and 
endothelium-independent CBFR vasodilator administrations 
were similar in patients with normal or decreased LV 
systolic function. Other studies have shown differences 
in endothelium-dependent and independent CBFR in 
cases of hypertension3,6 and dilated cardiomyopathy.5 In 
hypertension, the CBF dynamic is more dependent on 
structural than functional vascular alterations. It should be 
noted that the ratio between the maximum flow obtained 
with acetylcholine and that recorded with adenosine, 
an indication of endothelial function, was comparable 
in both study groups and was similar to normal values 
described in the literature.3,15 Additionally, the increase in 
epicardial diameter of the anterior descending coronary 
artery with adenosine was comparable between groups, 
reinforcing a similarity in endothelial function. Because 
adenosine acts primarily on vessel resistance,16 the induced 
diameter increase is understood to derive from high shear 
stresses consistent with an increased CBF, mediated by the 
endothelium.8,17 This occurs even when an epicardial artery 
diameter measurement taken when adenosine is used is 
recorded synchronously with a microcirculation action peak 
(15 to 20 seconds). The necessary waiting time for maximum 
flow-dependent vasodilatation response is 50 to 60 seconds, 
as demonstrated in humans.18 However, it is possible that a 
greater interval between adenosine administration and the 
documentation of epicardial coronary artery diameter could 
lead to different results. 
The responses obtained with nitroglycerin show that 
conductance vessel vasodilatation capacity was comparable in 
both groups and was preserved, similar to previous reports.19 
This normal vasodilatation response to nitroglycerin indicates 
a preserved epicardial coronary artery structure.
These results do not support the hypothesis that ischemic 
alterations caused by endothelial dysfunction explain LV 
functional maladaptation in hypertensive heart disease. Other 
studies have shown that hypertension, in the absence of other 
risk factors, is not associated with coronary endothelial 
dysfunction.3,15
Interestingly, although the two groups did not differ 
in endothelium-independent CBFR, there was a positive 
correlation with LVFS. In other words, the higher the 
ventricular dysfunction, the lower the reserve. However, this 
correlation was not evidenced in the multivariate analysis. 
The inverse correlation between LV systolic function 
and LVFSS was previously described in the context of 
hypertensive heart disease.20 In our study, LVFSS represented 
one of two variables independently related to LVFS. It 
is well known that one of the strongest coronary blood 
flow determinants is myocardial oxygen intake. Although 
CBFR does not correlate with LVFS in the multiple linear 
regression model given LVFSS and DBP variables, one must 
consider that, when facing an increase in systolic stress, 
the CBFR may be inadequate for the increased myocardial 
oxygen intake. Thus, if CBFR is not a determining factor 
for systolic dysfunction, its reduction may contribute to the 
continuation and/or aggravation of this clinical condition. 
This study shows that an association also exists between 
DBP and LV systolic function. The observed BP decrease 
in Group 2 can be explained in terms of deteriorating 
ventricular function. 
It is important to emphasize that the study population 
consisted of hypertensive patients undergoing adequate 
long-term clinical treatment. It is possible that including 
patients who had not previously undergone treatment 
would have yielded different results. Antihypertensive drug 
treatment, particularly with calcium channel antagonists,21,22 
angiotensin-converting enzyme inhibitors,23 and angiotensin-
receptor blockers,24 can positively interfere with endothelial 
function and vascular remodeling. However, this fact 
does not diminish the significance of our findings. By 
contrast, it provides new perspectives for understanding 
how hypertension treatment can positively impact disease 
evolution.
Study limitations 
In this study, we did not use a normal control group, 
because this does not exist in practice, and it did not 
seem ethical to use an invasive methodology to conduct a 
characterization. In the literature, control groups consist of 
normal heart and angina patients with microcirculation disease 
(Syndrome X).25 We emphasize, however, that the values we 
obtained for endothelium-dependent and independent CBFR 
are very close to those reported in many studies.3,6,17
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